Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Non-Current Assets came in at $207.2 million in Q1 2026, down 7.14% YoY from $223.2 million in Q1 2025, and down 1.3% on a QoQ basis from $209.9 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Non-Current Assets data on file, last reported at $207.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 7.14% year-over-year to $207.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $829.5 million (down 9.43% YoY) and the FY2025 annual result came in at $209.9 million, down 7.84% from the prior year.
- Non-Current Assets slipped to $207.2 million in Q1 2026, from $209.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $250.8 million in Q4 2023 to a low of $24.8 million in Q2 2022.
- A 5-year average of $178.4 million and a median of $209.9 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets fell 27.75% — and 2023, when it jumped 719.88%.
- Tracing CPRX's Non-Current Assets over 5 years: stood at $54.8 million in 2022, then jumped by 357.44% to $250.8 million in 2023, then dropped by 9.16% to $227.8 million in 2024, then fell by 7.84% to $209.9 million in 2025, then fell by 1.3% to $207.2 million in 2026.
- The last three Non-Current Assets figures came in at $207.2 million (Q1 2026), $209.9 million (Q4 2025), and $199.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 207.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.22 Mn |
| Dec 31, 2025 | 209.95 Mn |
| Sep 30, 2025 | 199.15 Mn |
| Jun 30, 2025 | 213.18 Mn |
| Mar 31, 2025 | 223.15 Mn |
| Dec 31, 2024 | 227.80 Mn |
| Sep 30, 2024 | 233.01 Mn |
| Jun 30, 2024 | 231.93 Mn |
| Mar 31, 2024 | 242.07 Mn |
| Dec 31, 2023 | 250.79 Mn |
| Sep 30, 2023 | 221.19 Mn |
| Jun 30, 2023 | 202.93 Mn |
| Mar 31, 2023 | 208.32 Mn |
| Dec 31, 2022 | 54.82 Mn |
| Sep 30, 2022 | 56.80 Mn |
| Jun 30, 2022 | 24.75 Mn |
| Mar 31, 2022 | 25.78 Mn |
| Dec 31, 2021 | 27.68 Mn |
| Sep 30, 2021 | 30.45 Mn |
| Jun 30, 2021 | 32.83 Mn |